(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) announced Tuesday top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI, 600 mg intravenous [IV] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results